CF
VNDA icon

Corebridge Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Corebridge Financial’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,927
Closed -$128K – 2718
2025
Q1 		$128K Sell
27,927
-413
-1% -$1.93K ﹤0.01% 2308
2024
Q4 		$136K Sell
28,340
-2,139
-7% -$10.3K ﹤0.01% 2403
2024
Q3 		$143K Sell
30,479
-188
-0.6% -$1.01K ﹤0.01% 2417
2024
Q2 		$173K Buy
+30,667
New +$158K ﹤0.01% 2280

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Corebridge Financial's VNDA Position: Q2 2025 in Review

Corebridge Financial sold out of Vanda Pharmaceuticals (VNDA) in Q2 2025, closing a stake of 27,927 shares — an estimated $128K sold.

Corebridge Financial first reported a position in VNDA in Q2 2024 and held it in 4 quarters. The position peaked at $173K in Q2 2024. 139 funds tracked by Wall St. Rank hold VNDA as of Q2 2025.

  • Corebridge Financial reported no remaining Vanda Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 27,927 Vanda Pharmaceuticals shares in Q2 2025, an estimated $128K.
  • Corebridge Financial first reported a position in Vanda Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Vanda Pharmaceuticals position peaked at $173K in Q2 2024.
  • 139 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.